| 1 |
中华医学会肝病学分会，中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版)[J]. 临床肝胆病杂志,2015,31(12):1961-1979.
|
| 2 |
Larrat S, Vallet S, David-Tchouda S, et al. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin[J]. J Clin Microbiol,2015,53(7):2195-2202.
|
| 3 |
Kuntzen T, Timm J, Berical A, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients[J]. Hepatology,2008,48(6):1769-1778.
|
| 4 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol,2011,55(2):245-264.
|
| 5 |
王艳斌，谢雯. 《丙型肝炎防治指南(2015年更新版)》解读[J/CD]. 中华实验和临床感染病杂志(电子版),2015,9(6):729-732.
|
| 6 |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection[J]. J Hepatol,2014,60(2):392-420.
|
| 7 |
European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2014[J]. J Hepatol,2014,61(2):373-395.
|
| 8 |
HCV Guideance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J]. Hepatology,2015,62(3):932-954.
|
| 9 |
European Association for the Study of the Liver. Recommendations on treatment of hepatitis C 2015[J]. J Hepatol,2015,63(1):199-236.
|
| 10 |
Besse B, Coste-Burel M, Bourgeois N, et al. Genotyping and resistance profile of hepatitis C (HCV) genotypes 1-6 by sequencing the NS3 protease region using a single optimized sensitive method[J]. J Virol Methods,2012,185(1):94-100.
|
| 11 |
Asselah T, Boyer N, Saadoun D, et al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives[J]. Liver Int,2016,36(Suppl 1):S47-S57.
|
| 12 |
Schneider MD, Kronenberger B, Zeuzem S, et al. Treatment of hepatitis C[J]. Revue Médicale De Bruxelles,2007,116(15):1792-1794.
|
| 13 |
Kanda T, Nakamoto S, Nakamura M, et al. Direct-acting antiviral agents for the treatment of chronic hepatitis c virus infection[J]. Expert Opinion on Investigational Drugs,2014,2(1):1-6.
|
| 14 |
戴明佳，颜学兵. 2014年IDSA及ASSLD联合发布抗HCV治疗指南解读[J/CD]. 中华实验和临床感染病杂志(电子版),2015,9(4):442-446.
|
| 15 |
戴明佳，方圆，李春杨, 等. 丙型肝炎直接抗病毒药物的发展现状[J]. 国际流行病学传染病学杂志,2014,41(6):412-415.
|
| 16 |
饶慧英，魏来. 2015年欧洲肝病学会丙型肝炎治疗推荐意见[J]. 临床肝胆杂志,2015,31(7):1008-1007.
|
| 17 |
Foster GR, Pianko S, Cooper C, et al. Sofosbuvir 1 peginterferon/ribavirin for 12 weeks vs. sofosbuvir1ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatmentexperienced cirrhotic patients with genotype 2 HCV: the BOSON study[C]. The 50th Annual Meeting of the European Association for the Study of the Liver (EASL),2015. Vienna, Austria.
|
| 18 |
戴明佳，方圆，李春杨, 等. 欧洲肝病学会最新HCV治疗指南解读及分析[J]. 中华实验和临床感染病杂志(电子版),2015,9(1):126-129.
|
| 19 |
戴明佳，颜学兵, 欧美2014年版抗HCV治疗指南比较分析[J]. 国际流行病学传染病学杂志,2015,42(2):76-79.
|
| 20 |
戴明佳，颜学兵. 2014年与2015年欧洲肝病学会抗HCV治疗指南比较[J]. 临床肝胆病杂志,2015,31(10):1595-1598.
|
| 21 |
Schneider MD, Sarrazin C. Antiviral therapy of hepatitis C in 2014: Do we need resistance testing?[J]. Antivir Res,2014,105(3):64-71.
|
| 22 |
Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naïve patients prior to treatment[J]. J Virol,2013,87(3):1544-1553.
|
| 23 |
Gaudieri S, Rauch A, Pfafferott K, et al. Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy[J]. Hepatology,2009,49(4):1069-1082.
|